Inflammation Proteomic Profiling of Psychosis in Young Adults: findings from the ALSPAC birth cohort 2 3 4 Authors: Ruby S. M. Tsang^{1,2,3} 5 Nicholas J. Timpson^{1,2} 6 Golam M. Khandaker^{1,2,3,4} 7 8 9 Affiliations: 10 ¹ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK ² Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 11 ³ Centre for Academic Mental Health, Population Health Sciences, University of Bristol, 12 13 Bristol, UK ⁴ NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS 14 15 Foundation Trust, Bristol, UK 16 17 Corresponding author: 18 Ruby Tsang 19 Population Health Sciences, Bristol Medical School 20 Oakfield House, Oakfield Grove 21 Bristol BS8 2BN 22 United Kingdom 23 ruby.tsang@bristol.ac.uk 24 25 Declaration of Interest: None.

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Psychotic disorder is associated with altered levels of various inflammatory markers in blood, but existing studies have typically focused on a few selected biomarkers, have not examined specific symptom domains notably negative symptoms, and are based on individuals with established/chronic illness. Based on data from young people aged 24 years from the Avon Longitudinal Study of Parents and Children (ALSPAC), a UK birth cohort, we have examined the associations of 67 plasma immune/inflammatory proteins assayed using the Olink Target 96 Inflammation panel with psychotic disorder, positive (any psychotic experiences and definite psychotic experiences) and negative symptoms, using linear models with empirical Bayes estimation. The analyses included between 2641 and 2854 individuals. After adjustment for age, sex, body mass index and smoking and correction for multiple testing, upregulation of CDCP1 and IL-6 were consistently associated with positive symptoms and psychotic disorder, while psychotic disorder was additionally associated with upregulation of MMP-10. Negative symptoms were associated with upregulation of the highest number of proteins (n=11), including cytokines, chemokines and growth factors which partly overlap with proteins associated with positive symptoms or psychotic disorder (CDCP1, IL-6 and MMP-10). Our findings highlight associations of inflammatory proteins involved in immune regulation, immune cell activation/migration, blood-brain barrier disruption, and extracellular matrix abnormalities with psychosis or psychotic symptoms in young people, consistent with a role of inflammation and immune dysfunction in the pathogenesis of psychotic disorders. Keywords: ALSPAC; psychosis; proteomics; inflammation; inflammatory markers; positive symptoms; negative symptoms

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Tsang et al.

1. Introduction Psychosis is an umbrella term that refers to a group of complex neuropsychiatric disorders primarily characterized by positive (e.g., hallucinations, delusions, or confusion) and negative symptoms (e.g., apathy and diminished expression). The median lifetime prevalence for schizophrenia, the archetypal psychotic disorder, is 4.0 per 1000 persons (McGrath et al., 2008), whereas it is 7.5 per 1000 persons for all psychoses (Moreno-Küstner et al., 2018). In contrast, subthreshold psychosis-like experiences are relatively common and are experienced by approximately a quarter of the general population during their lifetime (Bourgin et al., 2020). It has been suggested that the psychosis phenotype is expressed on a continuum, where symptoms may present in non-clinical populations (van Os et al., 2009). Schizophrenia is a multifactorial condition with both genetic and environmental contributions. Infection, inflammation and immune dysfunction have been implicated in the pathogenesis of schizophrenia and related psychoses (Benros et al., 2011; Brown and Derkits, 2010; Goldsmith et al., 2016; Khandaker et al., 2015). There is substantial evidence for crosssectional associations between central and peripheral inflammation and schizophrenia spectrum disorders. Abnormal cerebrospinal fluid (CSF) markers were observed in individuals with schizophrenia spectrum disorders, including elevated total protein, albumin ratio, white blood cell count, glucose, IL-6 and IL-8 levels (Warren et al., 2024). Blood concentrations of a number of inflammatory markers, namely interleukin (IL)-1β, IL-1 receptor antagonist (IL-1RA), soluble IL-2 receptor (sIL-2R), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) were consistently elevated in individuals with schizophrenia-spectrum disorder compared to healthy controls (Halstead et al., 2023). Subsets of cytokines may be associated with specific features of the disorder, for instance IL-2 and interferon (IFN)-y were elevated in acute schizophrenia-spectrum disorder whereas IL-4, IL-12 and IFN-γ were reduced in chronic schizophrenia-spectrum disorder (Halstead et al., 2023); another study found elevated IL-6, IL-12, IL-17 and IFN-y levels were observed in

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Tsang et al.

antipsychotic-naïve first-episode psychosis (FEP) while elevated IL-1β, IL-2, IL-4, IL-6 and TNF- α as well as reduced IL-10, were associated with negative symptoms (Dunleavy et al., 2022). Increased total white blood cell, monocyte and neutrophil counts were also observed in schizophrenia and FEP (Jackson and Miller, 2020). Similar dysregulations of inflammatory markers are also seen in those with subthreshold or transitory symptoms; when comparing subgroups with familial risk and clinical risk of psychosis with controls, the clinical risk subgroup showed higher IL-6 levels than controls, but the study did not find any evidence for markers that predicted transition to psychosis (Misiak et al., 2021). Longitudinally, exposures to inflammation during gestation and in childhood have been shown to be associated with psychosis risk. Prenatal exposure to infections and elevated proinflammatory cytokines may be associated with schizophrenia risk and structural and functional brain abnormalities relevant to schizophrenia, though effects may differ by infectious agent and timing of exposure (Khandaker et al., 2013). Furthermore, childhood viral infections involving the central nervous system may be associated with an increased risk of adult schizophrenia (Khandaker et al., 2012). Studies using data from the Avon Longitudinal Study of Parents and Children (ALSPAC) also showed that circulating IL-6 and CRP levels assessed in childhood and adolescence predicted psychosis or schizophrenia risk in adulthood (Khandaker et al., 2014; Metcalf et al., 2017), suggesting that immuneinflammatory changes predate the onset of psychosis or schizophrenia. Two other studies using ALSPAC data compared protein expression levels in childhood between those who did and did not later develop psychotic experiences or disorder in early adulthood, and found dysregulation of the complement and coagulation system was associated with psychosis risk (English et al., 2017; Föcking et al., 2021). Genome-wide association studies have identified multiple loci associated with schizophrenia risk, with strongest effects seen from variations in the major histocompatibility complex locus and particularly in complement component 4 genes, implicating immune function and

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

Tsang et al.

complement activity in the pathogenesis of schizophrenia (Sekar et al., 2016). Furthermore, Mendelian randomization studies support a potentially causal role of IL-6 signaling in schizophrenia, with increased levels of IL-6 and soluble IL-6 receptor (sIL-6R) associated with a higher risk of schizophrenia; additionally, IL-6 appeared to explain the previously reported protective effect of CRP (Hartwig et al., 2017; Perry et al., 2021). While existing studies support a role of inflammation in psychosis, there are key gaps in knowledge. For instance, most existing studies have typically focused on a limited number of inflammatory markers, but examining a larger immune proteomic panel can yield greater system-level insights into the pathophysiology of psychosis. Negative symptoms are core to schizophrenia, but there are relatively fewer studies of inflammation and negative symptoms compared to that of positive symptoms (Dunleavy et al., 2022). Negative symptoms represent an unmet clinical need as existing antipsychotic drugs do not adequately improve these symptoms. There is some evidence that inflammatory markers are associated with negative symptoms (Dunleavy et al., 2022; Khandaker et al., 2021); therefore, further studies are needed to examine these associations to understand whether inflammation could be a treatment target for negative symptoms. Finally, most existing studies are based on adults with established psychotic disorder. Studies of people who are relatively early on in the course of illness are required to identify immunological factors that are potentially relevant for incidence, rather than chronicity/prognosis. Studies of young people are also advantageous as this group is relatively unaffected by confounding from chronic inflammation-related diseases of adulthood. We present a study examining the associations of a range of inflammatory proteins, assessed using a proteomic panel, with psychotic disorder and positive and negative symptoms of psychosis at age 24 years using data from the Avon Longitudinal Study of Parents and Children (ALSPAC), a UK birth cohort. The aim of this study was to examine the

plasma inflammatory proteomic profile of psychotic disorder, and to compare patterns of associations for positive and negative symptoms in young adults. 2. Materials and Methods 2.1. Cohort and sample selection Pregnant women resident in Avon, United Kingdom with expected dates of delivery between 1st April 1991 and 31st December 1992 were invited to take part in the Avon Longitudinal Study of Parents and Children (ALSPAC) (Boyd et al., 2012; Fraser et al., 2012; Northstone et al., 2019). The initial number of pregnancies enrolled was 14,541 and 13,988 children were alive at 1 year of age. Additional recruitment took place when the oldest children were approximately 7 years of age. The total sample size for analyses using any data collected after the age of seven is therefore 15,447 pregnancies, with 14,901 children who were alive at 1 year of age (Generation 1). The present study focuses on the subset of Generation 1 participants who had data available for the relevant exposures (psychotic experiences, psychotic disorder, or negative symptoms), outcomes (blood immunological protein levels), and covariables (age, sex at birth, body mass index [BMI], and smoking). The sample selection flow diagram is presented in Figure 1. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the University of Bristol (Harris et al., 2009). REDCap is a secure, web-based software platform designed to support data capture for research studies. Please note that the study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/researchers/our-data/).

2.2. Ethics

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.




Figure 1. Flow diagram showing data availability in Generation 1 of ALSPAC for the analyses conducted.

183

184

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

Tsang et al.

2.3. Psychosis-related measures at age 24 Psychotic experiences (PEs) and disorder were identified through the face-to-face, semistructured Psychosis-Like Symptoms Interview (PLIKSi) administered by trained psychology graduates. The PLIKSi consists of 12 core items derived from the Diagnostic Interview Schedule for Children, Version IV (DISC-IV) (Shaffer et al., 2000) and the Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0 (SCAN 2.0) (World Health Organization Division of Mental Health, 1994). These items assess the presence, frequency and context of experiences associated with psychosis from three main domains of positive psychotic symptoms: hallucinations (visual and auditory), delusions (spied on, persecution, thoughts read, reference, control, grandiosity and other), and experiences of thought interference (broadcasting, insertion and withdrawal). Coding of all items followed glossary definitions, assessment, and rating rules for the SCAN 2.0. The PLIKSi administered at age 24 showed good inter-rater and test-retest reliability (intraclass correlation=0.81 [95% CI = 0.68-0.89] and intraclass correlation=0.90 [95% CI = 0.83-0.95]) (Sullivan et al., 2020). Individuals who self-reported PEs were cross-questioned to verify the presence of each of these experiences, which were then rated by interviewers as: PEs not present, suspected PEs, or definite PEs. Cases of psychotic disorder were defined as having an interviewerrated definite PE not attributable to the effects of sleep or fever, with recurring symptoms of at least once a month over the prior 6 months, which the individual reported as either very distressing, or had a negative impact on their social or occupational life, or led them to seek professional help (Zammit et al., 2013). Negative symptoms such as apathy, anergia and asociality were assessed using 10 questions based on the Community Assessment of Psychic Experiences (CAPE) self-report questionnaire, where each item was rated on a 4-point scale (0=never; 1=sometimes;

except where all items were missing, the sum score was coded as missing. We then derived

2=often; 3=always) and summed. Missing items were handled with median replacement,

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

Tsang et al.

a binary variable based on the sum score, and we assigned those with a score of 14 or above into the 'high negative symptoms' group (Jones et al., 2016); this corresponded to 13.9% of the sample. For the set of analyses looking at positive symptoms, the exposures were: i) 'any PEs': presence of any PEs, suspected or definite, not attributable to the effects of sleep or fever, ii) 'definite PEs': presence of any definite PEs not attributable to the effects of sleep or fever and iii) psychotic disorder as described above. The control group was defined as those who did not meet criteria for suspected/definite PEs or psychotic disorder. For the analysis looking at negative symptoms, the exposure was presence of high negative symptoms. 2.4. Blood inflammatory proteins at age 24 years Blood samples were collected in lithium heparin tubes and placed on ice until processing. Samples were spun at 1300g for 10 minutes at 4-5°C, then plasma was aliquoted from the tube and stored at -80°C. Target time from sample collection until plasma frozen was 90 minutes. Heparin-stored plasma samples collected from at approximately age 24 (fasting) were analyzed using the Olink Target 96 Inflammation panel (Olink Analysis Service, Uppsala, Sweden). The Olink Target 96 Inflammation panel measures a selection of 92 proteins involved in inflammatory and immune response processes. Data were returned in Normalised Protein expression (NPX) values on a log₂ scale, which are calculated from protein concentrations (cycle threshold [Ct] values) with normalization to minimize intra- and inter-assay variation (Olink Proteomics, 2021). Further details on the proteins assayed and quality control procedures applied have been previously reported (see data note by Goulding et al., 2024). Samples that did not pass Olink's quality control were excluded from the analysis. Proteins with ≥50% values below the limit of detection (LOD) were excluded (based on values reported in the relevant ALSPAC data note (Goulding et al., 2024); namely ARTN, Beta-NGF,

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

FGF-23, FGF-5, GDNF, IL-1 alpha, IL-10RA, IL-13, IL-15RA, IL-17A, IL-2, IL-20, IL-20RA, IL-22 RA1, IL-24, IL-2RB, IL-33, IL-4, IL-5, LIF, NRT, NT-3, SIRT2, SLAMF1, TSLP), leaving 67 proteins to be used as outcomes in the analyses (Table S1). NPX values beyond 5 standard deviations (SD) from the mean were recoded as missing. No further normalization procedures were applied to the proteomic data prior to analysis, as it will reduce information available for the empirical Bayes estimation used in the analysis. 2.5. Covariables BMI was computed using the formula: weight (kg) / height² (m²), and we recoded values of <15 or >=60 as missing. Smoking was assessed via a questionnaire, and we derived a composite smoking variable by coding those who self-reported having smoked in the past 30 days and ≥1 cigarettes per day or ≥7 per week as smokers. 2.6. Statistical analysis Sociodemographic characteristics of cases and controls were summarized as n (%), mean (standard deviation) or median [interquartile range] depending on the variable type (continuous or categorical). Group comparisons were conducted using Fisher's exact tests for categorical variables, t-tests for normally distributed continuous variables and Kruskal-Wallis tests for non-normally distributed continuous variables. Prior to analysis, correlations between inflammatory proteins were examined using Spearman's rho (Figure S1) and a principal component analysis was performed to examine the overall distribution of the data and identify potential sample clustering in the inflammation proteomics panel. There was evidence for clustering effects by sex and BMI, but not by age, smoking, batch, or plate (Figure S2). Associations between each case definition and inflammatory proteins were evaluated using multiple linear models fitted in the limma R package (Ritchie et al., 2015), which uses an empirical Bayes method to moderate the standard errors of the estimated log-fold changes by accounting for information from other

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

Tsang et al.

markers. For each of the case definitions, we ran a set of unadjusted models and a set of adjusted models with age, sex at birth, BMI and smoking as covariables. Correction for multiple comparisons was performed using the Benjamini-Hochberg procedure with a false discovery rate (FDR) adjusted p-value threshold of <0.05. We did not apply a fold change threshold as the effects are expected to be small in multifactorial phenotypes in a populationbased sample. We then examined protein-protein interactions (PPI) between the identified differentially abundant proteins at the nominal p < 0.05 level (separately for positive and negative symptoms) and functional enrichment in STRING database (version 12.0; https://stringdb.org) (Szklarczyk et al., 2019). We used 66 out of the 67 proteins included in the analysis as the statistical background as STRING was not able to map VEGF-A to an entry in the database. Data extraction and initial data cleaning was performed in StataMP 18 (StataCorp, 2023). Further data preparation and statistical analyses were conducted in RStudio 2022.07.1 using R v4.2.1 (R Core Team, 2022), using packages tidyverse (v2.0.0), haven (v2.5.2), reshape2 (v1.4.4), tableone (v0.13.2), and limma (v3.54.2). Plots were generated using ggplot2 (v3.4.2), ggfortify (v0.4.16), ggrepel (v0.9.3), and ggpubr (v0.6.0). 3. Results 3.1. Sample characteristics Characteristics of the controls (n=2574) and any PEs (n=280), definite PEs (n=169), and psychotic disorder groups (n=67) at age 24 years from the ALSPAC birth cohort are presented in **Table 1**. Group comparisons revealed individuals in the psychotic disorder group were more likely to be female, those in the any PEs group were more likely to have higher BMI and all case groups were more likely to be smokers and report higher negative symptoms than controls. Comparisons between individuals with and without high negative

symptoms showed that individuals with high negative symptoms (n=390) were marginally older, more likely to be smokers and less likely to have risky alcohol consumption than those with low or no negative symptoms (**Table 2**).

Table 1. Sociodemographic and lifestyle characteristics of the included sample by psychosis outcome

	Controls	Any PEs	Definite PEs	Psychotic
	(n=2574)	(n=280)	(n=169)	disorder
				(n=67)
Age (years), mean	24.03 (0.85)	24.11 (0.83)	24.10 (0.84)	24.06 (0.83)
(SD)				
Sex at birth	1623 (63.1%)	178 (63.6%)	111 (65.7%)	53 (79.1%)*
(female), n (%)				
BMI, mean (SD)	23.55 [21.45,	24.35 [21.44,	23.51 [21.26,	23.20 [20.29,
	26.68]	28.69]*	28.35]	28.66]
Smoking (Yes), n	690 (26.8%)	117	74 (43.8%)***	28 (41.8%)*
(%)		(41.8%)***		
AUDIT-C score,	5.00 [4.00,	5 [3.00, 7.00]	5.00 [3.00, 7.00]	5.00 [3.00,
median [IQR]	7.00]			6.25]
CAPE score,	6.00 [3.00,	10.00 [6.00,	11.00 [6.00,	12.50 [8.00,
median [IQR]	10.00]	15.00]***	16.25]***	19.00]***

Note: Group comparisons were conducted using chi-square tests for categorical variables, t-test for normally distributed continuous variables and Kruskal-Wallis tests for non-normally distributed continuous variables. *p<0.05, **p<0.01, ***p<0.001.

Abbreviations: BMI – body mass index; CAPE – Community Assessment of Psychic

Experiences; IQR – interquartile range

Table 2. Sociodemographic and lifestyle characteristics by level of negative

symptoms

311

312

313

314

315

316

317

318

	No/low negative symptoms	High negative symptoms
	(CAPE score < 14)	(CAPE score ≥ 14)
	(n = 2409)	(n = 390)
Age (years), mean (SD)	24.03 (0.84)	24.12 (0.87)*
Sex at birth (female), n (%)	1535 (63.7%)	233 (59.7%)
BMI, mean (SD)	23.58 [21.48, 26.64]	23.81 [21.16, 28.19]
Smoking (Yes), n (%)	646 (26.8%)	142 (36.4%)***
AUDIT-C score, median	5.00 [4.00, 7.00]	5.00 [3.00, 6.00]***
[IQR]		

Note: Group comparisons were conducted using chi-square tests for categorical variables, t-test for normally distributed continuous variables and Kruskal-Wallis tests for non-normally distributed continuous variables. *p<0.05, **p<0.01, ***p<0.001.

Abbreviations: BMI – body mass index; IQR – interquartile range

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345


346

Tsang et al.

3.2. Differentially abundant inflammatory proteins in psychosis and related outcomes The condition 'any PEs' was associated with upregulation of 22 inflammatory proteins after covariable adjustment; p-values of 6 of these associations survived FDR correction, which are CUB domain-containing protein 1 (CDCP1), TNF-related apoptosis-inducing ligand (TRAIL), IL-6, hepatocyte growth factor (HGF), monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor A (VEGF-A) (Figure 2B). Definite PEs were associated with upregulation of 17 proteins after covariable adjustment, but only CDCP1 and IL-6 survived FDR correction (Figure 2B). Psychotic disorder was associated with upregulation of 11 proteins after covariable adjustment and evidence for three of these proteins, namely CDCP1, IL-6 and matrix metalloproteinase-10 (MMP-10), remained after FDR correction (Figure 2B). Full results for each of these models can be found in the Supplementary Material. High negative symptoms were associated with upregulation of 23 proteins after covariable adjustment, 11 of which survived FDR correction. These proteins were HGF, MMP-10, IL-6, CDCP1, C-C motif chemokine ligand (CCL) 11, TRAIL, C-X3-C motif chemokine ligand 1 (CX3CL1), Fms-related receptor tyrosine kinase 3 ligand (FLT3L), fibroblast growth factor 21 (FGF-21), IL-10 receptor subunit beta (IL-10RB), CCL25 (Table 3). Full results can be found in the Supplementary Material. A total of 15 proteins showed upregulation in both positive and negative symptoms (using the nominal p-value cutoff of 0.05), which are CCL11, CCL25, T-cell surface glycoprotein CD5 (CD5), FGF-19, FGF-21, HGF, IL-6, latency-associated peptide transforming growth factor beta-1 (LAP TGF-β1), MCP-1, MMP-10, stem cell factor (SCF), transforming growth factor alpha (TGF-α), tumor necrosis factor receptor superfamily member 9 (TNFRSF9), and TRAIL.

3.3. Protein-protein interactions (PPI) and functional enrichment

Most identified differentially abundant proteins were functionally associated with each other within the protein-protein interaction network, suggesting they jointly contribute to shared functions (**Figures S3-S4**). However, the network showed no evidence of PPI or functional enrichment of Gene Ontology terms against the statistical background of the included list of proteins.






Figure 2. Differentially abundant blood inflammatory proteins associated with any psychotic experiences not attributable to sleep or fever, definite psychotic experiences not attributable to sleep or fever, and psychotic disorder.

Panels A and B show results from unadjusted and adjusted models respectively. The labelled points are proteins that reach a nominal p < 0.05, and those in orange indicates upregulated proteins that survived FDR correction.

Table 3. Inflammatory proteins associated with high negative symptoms, before and after FDR correction.

Protein	Log ₂ fold	Fold	t-statistic	p-value	FDR adjusted
	change	change			p-value
HGF	0.07	1.05	4.07	4.78e-5	3.20e-3
MMP-10	0.13	1.10	3.85	1.18e-4	3.97e-3
IL-6	0.13	1.10	3.69	2.27e-4	5.08e-3
CDCP1	0.08	1.06	3.60	3.23e-4	5.41e-3
CCL11	0.05	1.04	3.41	6.58e-4	8.82e-3
TRAIL	0.06	1.04	3.32	9.22e-4	1.03e-2
CX3CL1	0.07	1.05	3.27	1.08e-3	1.03e-2
FLT3L	0.07	1.05	2.98	2.94e-3	2.22e-2
FGF-21	0.22	1.17	2.97	2.98e-3	2.22e-2
IL-10RB	0.05	1.03	2.88	4.06e-3	2.72e-2
CCL25	0.09	1.06	2.69	7.22e-3	4.40e-2
IL-18R1	0.06	1.04	2.58	9.92e-3	5.42e-2
SCF	0.06	1.04	2.56	1.05e-2	5.42e-2
CCL19	0.09	1.06	2.47	1.37e-2	6.56e-2
TGF-α	0.03	1.02	2.39	1.67e-2	7.46e-2
CD5	0.04	1.03	2.37	1.79e-2	7.50e-2
TWEAK	0.05	1.03	2.32	2.06e-2	8.12e-2
MCP-1	0.05	1.03	2.20	2.79e-2	9.99e-2
CCL20	0.10	1.08	2.19	2.83e-2	9.99e-2
FGF-19	0.10	1.07	2.05	4.02e-2	1.34e-1
IL-18	0.06	1.04	2.03	4.21e-2	1.34e-1
TNFRSF9	0.04	1.03	2.00	4.53e-2	1.34e-1
LAP TGF-	0.03	1.02	1.99	4.52e-2	1.34e-1

Tsang	et	al
ISALIA	$-\iota$	aı.

beta1

360

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

Tsang et al.

4. Discussion Our study aimed to identify the plasma immune-inflammatory proteomic profile of psychotic disorder and related outcomes (positive and negative symptoms) in young adults using data from a well-phenotyped birth cohort. We observed upregulation of six, two and three proteins in any PEs, definite PEs and psychotic disorder respectively after covariable adjustment and FDR correction; CDCP1 and IL-6 were common to all three positive symptom case definitions and psychotic disorder was additionally associated with upregulation of MMP-10. We found upregulation of 11 protein in those with high negative symptoms, including CDCP1, IL-6 and MMP-10. These alterations were of relatively small magnitude, with many showing less than 10% upregulation, but more substantial fold changes were seen in the psychotic disorder group, where there were between 17% and 26% increases in CDCP1, IL-6 and MMP-10 levels. We observed alterations in different types of proteins, including growth factors, cytokines, chemokines, and matrix metalloproteinases that play roles in immune regulation, T cell activation and migration, macrophage activation and potentially blood-brain barrier (BBB) disruption, suggesting widespread immunological alterations are involved in psychosis. We report consistent evidence for associations of IL-6 across all psychosis-related outcomes examined including positive, negative symptoms and psychotic disorder. IL-6 is a pleiotropic cytokine that plays a key role in the regulation of immune responses and inflammation. As the most frequently studied cytokine, there is considerable evidence that suggests circulating concentrations of IL-6 is elevated across the psychosis spectrum, including in those at risk of psychosis (Misiak et al., 2021), in antipsychotic-naïve FEP (Dunleavy et al., 2022) and in both acute and chronic schizophrenia spectrum disorder (Halstead et al., 2023). IL-6 has also been reported to be associated with negative symptoms (Dunleavy et al., 2022). Our findings support an ongoing clinical trial investigating whether inhibition of IL-6 signaling using an anti-IL6R monoclonal antibody, tocilizumab, improves negative symptoms in people

with psychosis (Foley et al., 2023). Due to the pleiotropic effects of IL-6, the specific

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

Tsang et al.

mechanisms underlying the associations between increased IL-6 and psychosis remain poorly understood and further research is required to elucidate the specific biological pathways and cascades involved. CDCP1 is a transmembrane glycoprotein with three extracellular CUB domains. It has typically been studied in the context of cancer due to its overexpression in solid tumors and is considered a key regulator of cancer metastasis through its roles in cell migration and invasion, and extracellular matrix degradation via MMP-9 secretion (Miyazawa et al., 2010). More recently, CDCP1 has been found to have immune regulatory roles; it is a ligand for CD6 and regulates T cell activation and migration (Envindah-Asonye et al., 2017), and reduced IL-6 production was observed in CDCP1 knockout mice in an animal model of Kawasaki disease (Lun et al., 2021). CDCP1 has been shown to participate in a CD6 tripartite receptor complex that induces cytoskeleton remodeling and cell barrier tight junction reduction in retinal pigment epithelium cells (Borjini et al., 2023), suggesting this process may underlie disruptions to tissue barriers caused by T cell-mediated inflammation. It is possible that this process also contributes to disrupted BBB and T cell infiltration into the central nervous system, leading to neuroinflammation and neuropsychiatric disorders such as psychosis and schizophrenia spectrum disorders. MMPs are a family of zinc-dependent endopeptidases that contribute to tissue remodeling by degradation of extracellular matrix components in normal physiological processes and pathological conditions. In recent years, MMP-9 emerged as a candidate involved the pathophysiology of schizophrenia, as it is known to regulate a range of neurodevelopmental processes including synaptic and dendritic spine plasticity, neuroinflammation and BBB permeability (Bitanihirwe and Woo, 2020; Chopra et al., 2019). Although studies examining the candidate functional single nucleotide polymorphism (SNP) -1562 C/T polymorphism (rs3918242) in the MMP9 gene reported conflicting results (Xia et al., 2019), there is

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

Tsang et al.

evidence for peripheral MMP-9 upregulation in schizophrenia spectrum disorders (Schoretsanitis et al., 2021). MMP-10, also known as stromelysin-2, is expressed by macrophages in response to injury, infection or transformation; it is a critical mediator of macrophage activation (McMahan et al., 2016) and has been shown to promote chronic inflammation (Sánchez et al., 2022). MMP-10 has rarely been studied in the context of neuropsychiatric disorders, and the limited literature has reported mixed findings in relation to schizophrenia. One study reported that elevated CSF MMP-10 levels were associated with major depressive disorder, but not schizophrenia (Omori et al., 2020); however, another study reported associations between epigenetic proxies of plasma concentrations of MMP-10 and clinical features of schizophrenia (Kiltschewskij et al., 2024). It has also been shown in vitro that MMP-10 can activate MMP-9 via proteolysis of its precursor pro-MMP9 (Nakamura et al., 1998) and thus may be involved in a cascade that impacts on neurodevelopment and neuroinflammation in psychosis and schizophrenia spectrum disorders. The novel markers of CDCP1 and MMP-10 suggest potential roles of BBB dysfunction and extracellular matrix abnormalities in the pathophysiology of psychosis. Neuroinflammation has been shown to contribute to neurovascular endothelial dysfunction and increased BBB permeability in schizophrenia (Najjar et al., 2017). Extracellular matrix abnormalities, including reduced perineuronal nets and reduced extracellular matrix gene expression in several brain regions (Pantazopoulos et al., 2021) and alterations in brain extracellular matrix composition (Rodrigues-Amorim et al., 2022) have also been reported in schizophrenia. Further research is required to better understand the cascade of events including disruption of BBB integrity and extracellular matrix abnormalities in the pathogenesis of psychosis.

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

Tsang et al.

As a result of the cross-sectional design used here, we cannot ascertain whether any of the protein associations are causal for psychosis. However, we looked up evidence of potential causality based on existing Mendelian randomization (MR) studies which use genetic variants as instrumental variables to assess whether the association between an exposure and an outcome is likely to be causal or result of residual confounding or reverse causation (Sanderson et al., 2022). Existing MR studies support a potential causal role of IL-6 in schizophrenia (Hartwig et al., 2017; Perry et al., 2021), with also weak evidence of MCP-1 (Perry et al., 2021) that was associated with both positive and negative symptoms in the present study. In addition, a more recent MR study involving 735 immune-related biomarkers reported MR evidence for potential causal effects with schizophrenia for several proteins we found to be associated with psychosis/psychotic symptoms in our sample. These include IL-6, IL-10RB, IL-18, LIF-R, CCL25, FGF-19, and MMP-10 (Dardani et al., 2024). In particular, the study by Dardani and colleagues reported stronger evidence of causality for FGF-19 and MMP-10, though the interpretation may be complicated due to the use of potentially complex genetic instruments derived from trans quantitative trait loci (trans-QTLs) associations. In addition, FGF19 also showed evidence of genetic colocalization whereby the locus associated with blood FGF-19 protein levels were also associated with schizophrenia (Zuber et al., 2022). Taken together, findings from our analysis reported here and existing MR studies suggest that FGF-19 and MMP-10 could be causally relevant for schizophrenia. These proteins (along with others highlighted by our study and existing MR studies) require further investigation. Strengths of this study include using detailed blood immune proteomic data, various psychosis-related outcomes across the psychosis spectrum as well as examining both positive and negative symptoms, as well as using a population-based young adult sample. There are several limitations to the existing study. Firstly, this study is cross-sectional in design, making it difficult to ascertain whether any observed associations are causal or result of reverse causality or residual confounding. Further research is required to replicate these

associations, determine the temporal order of events and investigate whether these associations are causal. Secondly, as the study sample is drawn from a population-based cohort, there is likely a larger degree of heterogeneity in symptom severity, phase, duration, psychotropic medication use and neuropsychiatric comorbidity within the case groups, for which we have not been able to adjust despite their potential effects on blood protein levels. Lastly, the case groups defined by positive symptoms are rather small and the analyses may be underpowered to detect smaller effects, which may explain why only few signals were found relative to the analysis involving negative symptoms.

5. Conclusions

Using data from a well characterized birth cohort, we report that IL-6 and CDCP1 are associated with psychotic disorder and positive symptoms of psychosis, while negative symptoms are associated with changes in a larger number of immune proteins which partly overlap with proteins associated with positive symptoms. In addition to IL-6 that is already well reported in the literature, we identified two novel inflammatory markers, CDCP1 and MMP-10, which are implicated in immune regulation, T cell activation and migration, macrophage activation, BBB disruption, and extracellular matrix abnormalities. Our findings suggest there are widespread alterations in different types of inflammatory markers in young people with psychosis or psychotic symptoms. This is consistent with a role of inflammation and immune dysfunction in the pathogenesis of psychotic disorders.

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

Tsang et al.

Funding RSMT is supported by the Tackling Multimorbidity at Scale Strategic Priorities Fund programme (MR/W014416/1) delivered by the Medical Research Council and the National Institute for Health Research in partnership with the Economic and Social Research Council and in collaboration with the Engineering and Physical Sciences Research Council. NJT is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z). GMK acknowledges funding support from the Medical Research Council (MRC), UK (MC_UU_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the University of Bristol. GMK acknowledges additional funding support from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care, UK. The UK Medical Research Council (MRC) and Wellcome (grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and RSMT and GMK will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Data collection on psychotic symptoms at the age 24 research clinic was specifically funded by the MRC (grant: MR/M006727/1) awarded to Prof. Stan Zammit. The funders had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. **CRediT authorship contribution statement** Ruby Tsang: Conceptualization, Formal analysis, Writing - original draft, Writing - review & editing

521 Nicholas Timpson: Conceptualization, Writing – review & editing, Supervision 522 Golam Khandaker: Conceptualization, Writing – review & editing, Supervision 523 524 **Acknowledgements** 525 We are extremely grateful to all the families who took part in this study, the midwives for their 526 help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer 527 and laboratory technicians, clerical workers, research scientists, volunteers, managers, 528 receptionists and nurses. 529

530 References 531 Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., 532 2011. Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-533 Year Population-Based Register Study. American Journal of Psychiatry 168, 1303-1310. 534 Bitanihirwe, B.K.Y., Woo, T.-U.W., 2020. A conceptualized model linking matrix 535 metalloproteinase-9 to schizophrenia pathogenesis. Schizophrenia Research 218, 28-35. Borjini, N., Lun, Y., Jang, G.-F., Crabb, J., Chen, Y., Crabb, J., Fox, D.A., Ivanov, A.I., Lin, F., 536 537 2023. CD6 triggers actomyosin cytoskeleton remodeling after binding to its receptor complex. 538 Journal of Leukocyte Biology 115, 450-462. 539 Bourgin, J., Tebeka, S., Mallet, J., Mazer, N., Dubertret, C., Le Strat, Y., 2020. Prevalence 540 and correlates of psychotic-like experiences in the general population. Schizophrenia 541 Research 215, 371-377. 542 Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, 543 A., Ring, S., Davey Smith, G., 2012. Cohort Profile: The 'Children of the 90s'—the index 544 offspring of the Avon Longitudinal Study of Parents and Children. International Journal of 545 Epidemiology 42, 111-127. 546 Brown, A.S., Derkits, E.J., 2010. Prenatal Infection and Schizophrenia: A Review of 547 Epidemiologic and Translational Studies. American Journal of Psychiatry 167, 261-280. 548 Chopra, S., Overall, C.M., Dufour, A., 2019. Matrix metalloproteinases in the CNS: 549 interferons get nervous. Cellular and Molecular Life Sciences 76, 3083-3095.

550 Dardani, C., Robinson, J.W., Jones, H.J., Rai, D., Stergiakouli, E., Grove, J., Gardner, R., 551 McIntosh, A.M., Havdahl, A., Hemani, G., Smith, G.D., Richardson, T.G., Gaunt, T.R., 552 Khandaker, G.M., 2024. Immunological Drivers and Potential Novel Drug Targets for Major 553 Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions. medRxiv, 554 2024.2002.2016.24302885. 555 Dunleavy, C., Elsworthy, R.J., Upthegrove, R., Wood, S.J., Aldred, S., 2022. Inflammation in 556 first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of 557 negative symptoms, a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 558 146, 6-20. 559 English, J.A., Lopez, L.M., O'Gorman, A., Föcking, M., Hryniewiecka, M., Scaife, C., 560 Sabherwal, S., Wynne, K., Dicker, P., Rutten, B.P.F., Lewis, G., Zammit, S., Cannon, M., 561 Cagney, G., Cotter, D.R., 2017. Blood-Based Protein Changes in Childhood Are Associated 562 With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case-Control 563 Study of the ALSPAC Longitudinal Birth Cohort. Schizophrenia Bulletin 44, 297-306. 564 Enyindah-Asonye, G., Li, Y., Ruth, J.H., Spassov, D.S., Hebron, K.E., Zijlstra, A., Moasser, 565 M.M., Wang, B., Singer, N.G., Cui, H., Ohara, R.A., Rasmussen, S.M., Fox, D.A., Lin, F., 566 2017. CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences 114, 567 E6912-E6921. 568 Föcking, M., Sabherwal, S., Cates, H.M., Scaife, C., Dicker, P., Hryniewiecka, M., Wynne, K., 569 Rutten, B.P.F., Lewis, G., Cannon, M., Nestler, E.J., Heurich, M., Cagney, G., Zammit, S., 570 Cotter, D.R., 2021. Complement pathway changes at age 12 are associated with psychotic 571 experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. 572 Molecular Psychiatry 26, 524-533.

573 Foley, E.M., Griffiths, S.L., Murray, A., Rogers, J., Corsi-Zuelli, F., Hickinbotham, H., Warwick, 574 E., Wilson, M., Kaser, M., Murray, G.K., Deakin, B., Jadon, D., Suckling, J., Barnes, N.M., 575 Upthegrove, R., Khandaker, G.M., 2023. Protocol for the Psychosis Immune Mechanism 576 Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-577 dose tocilizumab in patients with psychosis. BMJ Open 13, e067944. 578 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., 579 Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2012. 580 Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers 581 cohort. International Journal of Epidemiology 42, 97-110. 582 Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine 583 network alterations in psychiatric patients: comparisons between schizophrenia, bipolar 584 disorder and depression. Molecular Psychiatry 21, 1696-1709. 585 Goulding, N., Goudswaard, L., Hughes, D., Corbin, L., Groom, A., Ring, S., Timpson, N., 586 Fraser, A., Northstone, K., Suderman, M., 2024. Inflammation proteomics datasets in the 587 ALSPAC cohort [version 2; peer review: 2 approved]. Wellcome Open Research 7. 588 Halstead, S., Siskind, D., Amft, M., Wagner, E., Yakimov, V., Shih-Jung Liu, Z., Walder, K., 589 Warren, N., 2023. Alteration patterns of peripheral concentrations of cytokines and 590 associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic 591 review and network meta-analysis. The Lancet Psychiatry 10, 260-271. 592 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009. Research 593 electronic data capture (REDCap)—A metadata-driven methodology and workflow process 594 for providing translational research informatics support. Journal of Biomedical Informatics 42, 595 377-381.

596 Hartwig, F.P., Borges, M.C., Horta, B.L., Bowden, J., Davey Smith, G., 2017. Inflammatory 597 Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study. JAMA 598 Psychiatry 74, 1226-1233. 599 Jackson, A.J., Miller, B.J., 2020. Meta-analysis of total and differential white blood cell counts 600 in schizophrenia. Acta Psychiatrica Scandinavica 142, 18-26. 601 Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., 602 Lewis, G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O'Donovan, M.C., Owen, M.J., 603 Walters, J.T., Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia 604 During Adolescence in the General Population. JAMA Psychiatry 73, 221-228. 605 Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., 2015. 606 Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. 607 The Lancet Psychiatry 2, 258-270. 608 Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of 609 Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in 610 Young Adult Life: A Population-Based Longitudinal Study. JAMA Psychiatry 71, 1121-1128. 611 Khandaker, G.M., Stochl, J., Zammit, S., Lewis, G., Dantzer, R., Jones, P.B., 2021. 612 Association between circulating levels of C-reactive protein and positive and negative 613 symptoms of psychosis in adolescents in a general population birth cohort. Journal of 614 Psychiatric Research 143, 534-542. Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., 2012. Childhood infection 615 616 and adult schizophrenia: A meta-analysis of population-based studies. Schizophrenia 617 Research 139, 161-168.

618 Khandaker, G.M., Zimbron, J., Lewis, G., Jones, P.B., 2013. Prenatal maternal infection, 619 neurodevelopment and adult schizophrenia: a systematic review of population-based studies. 620 Psychological Medicine 43, 239-257. 621 Kiltschewskij, D.J., Reay, W.R., Geaghan, M.P., Atkins, J.R., Xavier, A., Zhang, X., Watkeys, 622 O.J., Carr, V.J., Scott, R.J., Green, M.J., Cairns, M.J., 2024. Alteration of DNA Methylation 623 and Epigenetic Scores Associated With Features of Schizophrenia and Common Variant 624 Genetic Risk. Biological Psychiatry 95, 647-661. 625 Lun, Y., Borjini, N., Miura, N.N., Ohno, N., Singer, N.G., Lin, F., 2021. CDCP1 on Dendritic 626 Cells Contributes to the Development of a Model of Kawasaki Disease. The Journal of 627 Immunology 206, 2819-2827. 628 McGrath, J., Saha, S., Chant, D., Welham, J., 2008. Schizophrenia: A Concise Overview of 629 Incidence, Prevalence, and Mortality. Epidemiologic Reviews 30, 67-76. 630 McMahan, R.S., Birkland, T.P., Smigiel, K.S., Vandivort, T.C., Rohani, M.G., Manicone, A.M., 631 McGuire, J.K., Gharib, S.A., Parks, W.C., 2016. Stromelysin-2 (MMP10) Moderates 632 Inflammation by Controlling Macrophage Activation. The Journal of Immunology 197, 899-633 909. 634 Metcalf, S.A., Jones, P.B., Nordstrom, T., Timonen, M., Mäki, P., Miettunen, J., Jääskeläinen, 635 E., Järvelin, M.-R., Stochl, J., Murray, G.K., Veijola, J., Khandaker, G.M., 2017. Serum C-636 reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth 637 cohort study. Brain, Behavior, and Immunity 59, 253-259.

638 Misiak, B., Bartoli, F., Carrà, G., Stańczykiewicz, B., Gładka, A., Frydecka, D., Samochowiec, 639 J., Jarosz, K., Hadryś, T., Miller, B.J., 2021. Immune-inflammatory markers and psychosis 640 risk: A systematic review and meta-analysis. Psychoneuroendocrinology 127, 105200. 641 Miyazawa, Y., Uekita, T., Hiraoka, N., Fujii, S., Kosuge, T., Kanai, Y., Nojima, Y., Sakai, R., 642 2010. CUB Domain-Containing Protein 1, a Prognostic Factor for Human Pancreatic 643 Cancers, Promotes Cell Migration and Extracellular Matrix Degradation, Cancer Research 644 70, 5136-5146. 645 Moreno-Küstner, B., Martín, C., Pastor, L., 2018. Prevalence of psychotic disorders and its 646 association with methodological issues. A systematic review and meta-analyses. PLOS ONE 647 13, e0195687. 648 Najjar, S., Pahlajani, S., De Sanctis, V., Stern, J.N.H., Najjar, A., Chong, D., 2017. 649 Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to 650 Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence. 651 Frontiers in Psychiatry 8. 652 Nakamura, H., Fujii, Y., Ohuchi, E., Yamamoto, E., Okada, Y., 1998. Activation of the 653 precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. 654 European Journal of Biochemistry 253, 67-75. 655 Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells, N., 2019. 656 The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled 657 sample of index children in 2019 [version 1; peer review: 2 approved]. Wellcome Open 658 Research 4. 659 Olink Proteomics, 2021. White paper: Data normalization and standardization.

660 Omori, W., Hattori, K., Kajitani, N., Okada-Tsuchioka, M., Boku, S., Kunugi, H., Okamoto, Y., 661 Takebayashi, M., 2020. Increased Matrix Metalloproteinases in Cerebrospinal Fluids of 662 Patients With Major Depressive Disorder and Schizophrenia. International Journal of 663 Neuropsychopharmacology 23, 713-720. 664 Pantazopoulos, H., Katsel, P., Haroutunian, V., Chelini, G., Klengel, T., Berretta, S., 2021. 665 Molecular signature of extracellular matrix pathology in schizophrenia. European Journal of 666 Neuroscience 53, 3960-3987. 667 Perry, B.I., Upthegrove, R., Kappelmann, N., Jones, P.B., Burgess, S., Khandaker, G.M., 668 2021. Associations of immunological proteins/traits with schizophrenia, major depression 669 and bipolar disorder: A bi-directional two-sample mendelian randomization study. Brain, 670 Behavior, and Immunity 97, 176-185. 671 R Core Team, 2022. R: A language and environment for statistical computing. R Foundation 672 for Statistical Computing, Vienna, Austria. 673 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., 2015. limma 674 powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic 675 Acids Research 43, e47-e47. 676 Rodrigues-Amorim, D., Rivera-Baltanás, T., Fernández-Palleiro, P., Iglesias-Martínez-677 Almeida, M., Freiría-Martínez, L., Jarmardo-Rodriguez, C., del Carmen Vallejo-Curto, M., 678 Álvarez-Ariza, M., López-García, M., de las Heras, E., García-Caballero, A., Olivares, J.M., 679 Spuch, C., 2022. Changes in the Brain Extracellular Matrix Composition in schizophrenia: A 680 Pathophysiological Dysregulation and a Potential Therapeutic Target. Cellular and Molecular 681 Neurobiology 42, 1921-1932.

682 Sánchez, K.E., Bhaskar, K., Rosenberg, G.A., 2022. Apoptosis-associated speck-like protein 683 containing a CARD-mediated release of matrix metalloproteinase 10 stimulates a change in 684 microglia phenotype. Frontiers in Molecular Neuroscience 15. 685 Sanderson, E., Glymour, M.M., Holmes, M.V., Kang, H., Morrison, J., Munafò, M.R., Palmer, 686 T., Schooling, C.M., Wallace, C., Zhao, Q., Davey Smith, G., 2022. Mendelian randomization. 687 Nature Reviews Methods Primers 2, 6. 688 Schoretsanitis, G., de Filippis, R., Ntogka, M., Leucht, S., Correll, C.U., Kane, J.M., 2021. 689 Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum 690 Disorders: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin 47, 986-996. 691 Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., 692 Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Daly, 693 M.J., Carroll, M.C., Stevens, B., McCarroll, S.A., Schizophrenia Working Group of the 694 Psychiatric Genomics, C., 2016. Schizophrenia risk from complex variation of complement 695 component 4. Nature 530, 177-183. 696 Shaffer, D., Fisher, P., Lucas, C.P., Dulcan, M.K., Schwab-Stone, M.E., 2000. NIMH 697 Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, 698 Differences From Previous Versions, and Reliability of Some Common Diagnoses. Journal of 699 the American Academy of Child & Adolescent Psychiatry 39, 28-38. 700 StataCorp, 2023. Stata Statistical Software: Release 18. StataCorp LLC, College Station, TX, 701 USA. 702 Sullivan, S.A., Kounali, D., Cannon, M., David, A.S., Fletcher, P.C., Holmans, P., Jones, H., 703 Jones, P.B., Linden, D.E.J., Lewis, G., Owen, M.J., O'Donovan, M., Rammos, A., Thompson,

704 A., Wolke, D., Heron, J., Zammit, S., 2020. A Population-Based Cohort Study Examining the 705 Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and 706 Prediction of Psychotic Disorder. American Journal of Psychiatry 177, 308-317. 707 Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., 708 Doncheva, N.T., Morris, J.H., Bork, P., Jensen, L.J., Mering, Christian v., 2019. STRING v11: 709 protein-protein association networks with increased coverage, supporting functional 710 discovery in genome-wide experimental datasets. Nucleic Acids Research 47, D607-D613. 711 van Os, J., Linscott, R.J., Myin-Germeys, I., Delespaul, P., Krabbendam, L., 2009. A 712 systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis 713 proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 39, 714 179-195. 715 Warren, N., O'Gorman, C., Horgan, I., Weeratunga, M., Halstead, S., Moussiopoulou, J., 716 Campana, M., Yakimov, V., Wagner, E., Siskind, D., 2024. Inflammatory cerebrospinal fluid 717 markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 718 studies with 5710 participants. Schizophrenia Research 266, 24-31. 719 World Health Organization Division of Mental Health, 1994. Schedules for Clinical 720 Assessment in Neuropsychiatry. American Psychiatric Press (on behalf of World Health 721 Organization), Washington, DC. 722 Xia, Q.-R., Zhang, C., Liang, J., Xu, Y.-Y., 2019. The association of functional polymorphism 723 of matrix metalloproteinase-9 gene (rs3918242) with schizophrenia: a meta-analysis. 724 International Journal of Psychiatry in Clinical Practice 23, 207-214.

Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis,
S., Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic Experiences and Psychotic Disorders
at Age 18 in Relation to Psychotic Experiences at Age 12 in a Longitudinal Population-Based
Cohort Study. American Journal of Psychiatry 170, 742-750.
Zuber, V., Grinberg, N.F., Gill, D., Manipur, I., Slob, E.A.W., Patel, A., Wallace, C., Burgess,
S., 2022. Combining evidence from Mendelian randomization and colocalization: Review
and comparison of approaches. The American Journal of Human Genetics 109, 767-782.

